Clinical Implications of Gynecologic Cancer

  • Georgios E. HilarisEmail author


The postmenopausal patient with new-onset vaginal bleeding should be assessed with transvaginal pelvic sonography. An endometrial thickness of ≤4 mm (ACOG) (or 5 mm by other societies) is a safe cutoff to defer endometrial sampling as the risk or endometrial malignancy is 1% unless the patient has persistent or intermittent bleeding where the risk may be higher [1].


  1. 1.
    Smith-Bindman R, Kerlikowske K et al (1998) Ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 280(17):1510CrossRefGoogle Scholar
  2. 2.
    Beddy P, Moyle P et al (2012) Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 262(2):530CrossRefGoogle Scholar
  3. 3.
    Park JY, Kim EN et al (2008) Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 108(3):486CrossRefGoogle Scholar
  4. 4.
    Fung-Kee-Fung M, Dodge J et al (2006) Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101(3):520CrossRefGoogle Scholar
  5. 5.
    Prat J (2014) FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 133:401–404CrossRefGoogle Scholar
  6. 6.
  7. 7.
    National Comprehensive Cancer Network (NCCN)Google Scholar
  8. 8.
    Buys SS, Partridge E et al (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. PLCO project team. JAMA 305(22):2295CrossRefGoogle Scholar
  9. 9.
    Kobayashi H, Yamada Y et al (2008) A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 18(3):414CrossRefGoogle Scholar
  10. 10.
    Menon U, Gentry-Maharaj A, Hallett R, Ryan A et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol 10(4):327CrossRefGoogle Scholar
  11. 11.
    JR Jr VN, Miller RW et al (2011) Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 118(6):1212CrossRefGoogle Scholar
  12. 12.
    NCCN Guidelines Version 2.2012: Epithelial ovarian cancer/fallopian tube cancer/ primary peritoneal cancer.
  13. 13.
    Benedet JL, Bender H et al (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet 70(2):209CrossRefGoogle Scholar
  14. 14.
    Elit L, Fyles AW et al (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114(3):528CrossRefGoogle Scholar
  15. 15.
    Salani R, Backes FJ et al (2011) Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncologists recommendations. Am J Obstet Gynecol 204(6):466CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.2nd Dept. of Gynecologic OncologyHygeia HospitalMarousiGreece
  2. 2.Division of Gynecologic OncologyStanford University School of MedicineStanfordUSA

Personalised recommendations